Federal Cannabis Status Unchanged Despite 38-State Patchwork

Federal Schedule I Classification Persists

Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, the strictest federal drug classification reserved for substances with no accepted medical use and high abuse potential. The Drug Enforcement Administration maintains this designation despite ongoing rescheduling petitions and a 2022 directive from President Biden to review cannabis's classification. Schedule I status subjects cannabis to the same federal enforcement framework as heroin, placing state-licensed operators in technical violation of 21 U.S.C. § 841, which criminalizes manufacturing and distribution.

The Department of Justice hasn't updated its enforcement priorities since the rescission of the Cole Memo in 2018. Federal prosecutors retain authority to prosecute cannabis offenses in all 50 states, though resource constraints and political considerations have limited such actions in recent years.

38 States Operate Licensed Markets Under State Law

Thirty-eight states and the District of Columbia have enacted medical or adult-use cannabis programs, creating a $32 billion regulated market that exists in direct conflict with federal statute. State licensing regimes authorize cultivation, processing, testing, and retail sales through agencies including California's Department of Cannabis Control, New York's Office of Cannabis Management, and Illinois's Cannabis Control Board. These programs generate tax revenue and employment. But they offer no protection from federal enforcement.

State-licensed operators face unique compliance burdens:

• Banking restrictions under the Bank Secrecy Act limit access to deposit accounts and merchant services
• Internal Revenue Code Section 280E prohibits deductions for ordinary business expenses, creating effective tax rates exceeding 70 percent
• Interstate commerce remains prohibited, forcing each state to maintain closed-loop supply chains
• Federal trademark protection is unavailable for cannabis products and brands

Congressional Inaction Leaves Conflict Unresolved

The 119th Congress hasn't advanced comprehensive cannabis reform legislation despite bipartisan support for banking access and criminal-record relief. The SAFE Banking Act, which would permit financial institutions to serve state-licensed cannabis businesses without federal penalty, passed the House in 2021 and 2023 but stalled in the Senate both times. The Cannabis Administration and Opportunity Act, introduced by Senate Majority Leader Chuck Schumer in 2022, didn't receive a committee vote.

No cannabis-reform bill has reached the Senate floor for a vote in the current session. Legislative observers attribute the stalemate to disagreements over social-equity provisions, tax rates, and whether to permit continued state prohibition.

Rescheduling Petition Remains Pending at DEA

A petition to reschedule cannabis to Schedule III, filed in response to President Biden's October 2022 directive, remains under review at the Drug Enforcement Administration with no announced timeline for a final rule. The Department of Health and Human Services completed its scientific review in August 2023 and recommended rescheduling to Schedule III, which would acknowledge accepted medical use and lower abuse potential than Schedule I or II substances.

Rescheduling to Schedule III wouldn't legalize cannabis under federal law but would eliminate the Section 280E tax penalty and align federal classification with FDA-approved cannabinoid medications including Epidiolex.

The DEA published a notice of proposed rulemaking in May 2024 and held a public comment period that closed in July 2024. Administrative-law judges haven't yet issued a recommended decision. For procedural background, see the CannIntel topic hub on federal cannabis legality.

Enforcement Priorities Remain Unclear

The Department of Justice hasn't issued formal guidance on cannabis enforcement since Attorney General Jeff Sessions rescinded the Cole Memo in January 2018. That memo, issued in 2013, directed federal prosecutors to deprioritize cannabis cases in states with strong regulatory frameworks. Its rescission returned discretion to individual U.S. Attorneys, though prosecutions of state-compliant operators have remained rare.

Federal agencies continue to enforce cannabis prohibitions in specific contexts:

• The Bureau of Alcohol, Tobacco, Firearms and Explosives prohibits cannabis users from purchasing firearms under 18 U.S.C. § 922(g)(3)
• U.S. Customs and Border Protection seizes cannabis at international borders and ports of entry
• The Transportation Security Administration refers cannabis discoveries to local law enforcement
• Federal employers, including the U.S. Postal Service and Department of Defense, maintain zero-tolerance drug policies

This legal ambiguity creates operational risk for multi-state operators, investors, and ancillary service providers including landlords, insurers, and payroll companies.